过剩3
过剩1
过剩2
过剩4
药理学
葡萄糖摄取
药物发现
化学
生物化学
计算生物学
基因
生物
生物技术
基因表达
葡萄糖转运蛋白
染色体易位
胰岛素
作者
Hölger Siebeneicher,Arwed Cleve,Hartmut Rehwinkel,Roland Neuhaus,Iring Heisler,Thomas Müller,Marcus Bauser,Bernd Buchmann
出处
期刊:ChemMedChem
[Wiley]
日期:2016-08-23
卷期号:11 (20): 2261-2271
被引量:326
标识
DOI:10.1002/cmdc.201600276
摘要
Abstract Despite the long‐known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1‐selective small‐molecule inhibitor. Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor. A high‐throughput screen against a library of ∼3 million compounds was performed to find a small molecule with this challenging potency and selectivity profile. The N ‐(1 H ‐pyrazol‐4‐yl)quinoline‐4‐carboxamides were identified as an excellent starting point for further compound optimization. After extensive structure–activity relationship explorations, single‐digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained. The most promising compound, BAY‐876 [ N 4 ‐[1‐(4‐cyanobenzyl)‐5‐methyl‐3‐(trifluoromethyl)‐1 H ‐pyrazol‐4‐yl]‐7‐fluoroquinoline‐2,4‐dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI